Genius Group has resumed buying Bitcoin, acquiring 10 BTC for about $854,000 between October 2 and 5 at an average price of $85,364 per BTC. This purchase is part of the company's broader $1.2 billion dual-treasury strategy aiming for $827 million in Bitcoin assets by fiscal 2031, alongside $800 million in AI assets and $2 billion in total assets. The company plans to fund these purchases through operating cash flow, preferred securities issuance, and stock offerings, explicitly avoiding debt financing or using its holdings as collateral. CEO Roger James Hamilton described this as a limited but significant restart of their Bitcoin accumulation strategy.
Genius Group's Bitcoin buying activity is noted here with Pluang's cryptocurrency market data for context. Of 50 major cryptocurrencies priced on Pluang, 5 rose and 44 fell today. UNI was priced at Rp142.635 with a 1-day change of -10.42%, DOT at Rp19.869 with -9.91%, and FIL at Rp18.964 with -8.78%, as of Oct 07, 2026 19:23 WIB.
Cincinnati Financial Corporation will release its third-quarter 2026 earnings after market close on October 26, 2026. The company will hold a conference call to discuss the results on October 27 at 11 a.m. ET, accessible via their investor website. T...
TE Connectivity plc will announce its financial results for the fourth quarter and full fiscal year 2026 on October 28, 2026, before the market opens. The company will host a conference call for investors at 8:30 a.m. ET on the same day, providing de...
Commvault has named Matthew Stauble as its new Chief Customer Officer to lead its global customer engineering teams, including sales engineering, customer success, and support. Stauble brings extensive experience from Alteryx and Palo Alto Networks, ...
AbbVie announced that the FDA has granted Breakthrough Therapy Designations (BTDs) for its investigational drug Temab-A (telisotuzumab adizutecan) in treating colorectal cancer (CRC) and non-small cell lung cancer (NSCLC). Temab-A, a next-generation ...
A Dutch court ruled that Merck infringed Halozyme's MDASE patent EP622 and ordered Merck's affiliate MSD BV to stop manufacturing, selling, and importing Keytruda SC in several European countries. The injunction covers Belgium, Denmark, France, Irela...
